Surveillance of bacterial resistance in Jinhua area of Zhejiang province in 2013

Quinupristin Dalfopristin Nitrofurantoin Enterococcus faecium Coagulase
DOI: 10.3760/cma.j.issn.1674-2397.2014.04.005 Publication Date: 2014-08-28
ABSTRACT
Objective To survey the distribution and drug resistance of clinical isolated bacteria in Jinhua area Zhejiang province 2013. Methods Clinical bacterial isolates were successively collected from seven general hospitals during January December 2013. Antimicrobial susceptibility testing was carried out using automated systems or by Kirby-Bauer method, results analyzed according to breakpoints Clinical Laboratory Standards Institute (CLSI) 2012. WHONET 5.6 software used for analysis. Results A total 22 830 collected, which 16 637 (72.8%) gram negative strains, 5 539 (24.3%) positive 654 (2.9%) yeasts. The average prevalence methicillin-resistant strains Staphylococcus aureus (MRSA) coagulase-negative Staphylococci (MRCNS) 37.5% 79.0%, respectively. rates most antimicrobial agents tested much higher than those methicillin-sensitive strains. More 90.0% susceptible nitrofurantoin rifampin, more 84% compound sulfamethoxazole. No vancomycin resistant observed. In Enterococcus spp., E. faecium (except quinupristin/dalfopristin tetracycline) fecalis, vancomycin-resistant observed both species. extended-spectrum β-lactamase (ESBLs)-producing 53.1% coli 27.3% Klebsialla on average. There 1 190 carbapenemsp-resistant Enterobacteriaceae Serratia marcescens had highest (42.0%-43.2%). Acinetobacter spp. imipenem meropenem up 39.9% 63.8%, Pseudomonas aeruginosa still highly sensitive including piperacillin, third fourth generation cephalosporins aminoglycosides. Candida krusei fluconazole, itraconazole voriconazole albicans, tropicalis Torulopsis glabrata. Conclusion Bacterial is becoming an increasingly worrisome problem province, especially emerging carbapenem-resistant Enterobacteriaceae. Key words: Drug resistance; Microbial sensitivity tests; Methicillin-resistant Staphylococci; Extended spectrum beta-lactamases
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES ()
CITATIONS ()
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....